Spartina Biotechnologies

About

About

OUR SOLUTION: Celerna™

Stopping the Spread of COVID-19 with RNAi

THE CHALLENGE:  How to activate and engage the innate immune systems to repress SARS-CoV-2 replication?

OUR SOLUTION:  We have designed a low-cost, targeted therapeutic RNA delivery system (Celerna™) to control coronavirus infections in humans. We use extracellular vesicles (EVs) to package, protect and deliver therapeutic RNA molecules to virus-infected cells or to cells having aberrant patterns of gene expression (Cancers) to mitigate disease.  Significantly, we can deliver therapeutic RNAs by multiple pathways including injection, by aerosols or orally using an FDA-approved probiotic.

Celerna™ technology has the potential to revolutionize human gene therapy and the control of viral pathogens by silencing specific targeted genes with virtually no off target effects. In addition, Celerna™ technology can be rapidly modified to address viral mutations that confer resistance to first generation products or for new emerging pathogen threats.

Spartina Biotech is based in Santa Fe New Mexico and works in partnership with Los Alamos National Laboratory and the New Mexico Consortium.

THE PROCESS

Research & Development Timeline

March 2020

Research Commenced

Q4 2021

Proof of Technology

2022

Clinical Trials

2022

Proof of Concept

2022 - 2023

Commercialization

WHAT WE DO

The Benefits of Celerna™ Technology

At Spartina Biotechnologies, we are developing a low-cost, safe RNA interference (RNAi) technology (Celerna™) for the prevention and treatment of Coronavirus infections.

Celerna™ technology has multiple attributes that provide for enhanced control of Coronavirus-associated morbidity and mortality. This is achieved by:

Rapidly (hours) activating innate immune pathways that have been demonstrated to suppress Coronavirus replication when activated

WHAT WE DO

The Benefits of Celerna™ Technology

At Spartina Biotechnologies, we are developing a low-cost, safe RNA interference (RNAi) technology (Celerna™) for the prevention and treatment of Coronavirus infections.

Celerna™ technology has multiple attributes that provide for enhanced control of Coronavirus-associated morbidity and mortality. This is achieved by:

Rapidly (hours) activating innate immune pathways that have been demonstrated to suppress Coronavirus replication when activated